Theriva Biologics (TOVX) reported second-quarter 2026 financial results and operational updates, including first patient dosing in the VIRAGE2 Phase 2a study of VCN-01 in metastatic pancreatic ductal adenocarcinoma. The company reported cash and cash equivalents of $11.3 million as of June 30, 2026, with a cash runway into Q1 2027.
For the quarter ended June 30, 2026, Theriva reported a net loss attributable to common stockholders of $3.2 million, or $0.07 per basic and diluted share. General and administrative expenses declined to $2.0 million from $11.2 million a year earlier, while research and development expenses fell to $1.3 million from $2.0 million.
- VIRAGE2 is evaluating at least 3 doses of VCN-01 given about 2 months apart with standard-of-care chemotherapy.
- The trial is expected to enroll 6 evaluable patients and complete enrollment in the second half of 2026.
- Initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027.
- The company plans to discuss a proposed Phase 2/3 retinoblastoma trial protocol with the FDA in Q3 2026.
- License revenue was $0 for the second quarter and $300,000 for the first six months of 2026.
$TOVX Hedge Fund Activity
We have seen 9 institutional investors add shares of $TOVX stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIRTU FINANCIAL LLC added 253,218 shares (+inf%) to their portfolio in Q1 2026, for an estimated $49,580
- GEODE CAPITAL MANAGEMENT, LLC added 238,176 shares (+112.3%) to their portfolio in Q1 2026, for an estimated $46,634
- JANE STREET GROUP, LLC added 177,034 shares (+inf%) to their portfolio in Q1 2026, for an estimated $34,663
- MORGAN STANLEY removed 176,398 shares (-88.2%) from their portfolio in Q1 2026, for an estimated $34,538
- TWO SIGMA SECURITIES, LLC added 62,348 shares (+145.4%) to their portfolio in Q1 2026, for an estimated $12,207
- XTX TOPCO LTD added 55,175 shares (+139.9%) to their portfolio in Q1 2026, for an estimated $10,803
- DRW SECURITIES, LLC removed 41,745 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,173
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
